Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer

European Urology
Kees HendricksenJ Alfred Witjes

Abstract

To study the additive effect of either an early instillation or maintenance instillations of adjuvant intravesical epirubicin, as compared to the epirubicin "standard" treatment schedule only, in patients with non-muscle-invasive bladder cancer. Patients with intermediate- and high-risk urothelial cell carcinoma of the bladder, except carcinoma in situ, were randomised for adjuvant intravesical instillations with 50mg epirubicin/50 ml NaCl for 1h. Group 1 received 4 weekly and 5 monthly instillations (standard schedule), group 2 received the same schedule as group 1, but with an additional instillation <48 h after transurethral resection of bladder tumour (TURBT), and group 3 received the same scheme as group 1, but with additional instillations at 9 and 12 mo (maintenance schedule). Standard follow-up was 5 yr and consisted of cystoscopy, cytology, and registration of adverse events. A total of 731 patients were eligible for quasi intention-to-treat analysis. Side-effects were minimal for all treatment groups. After 5-yr follow-up, respectively, 44.4%, 42.7%, and 45.0% (log-rank test, p=0.712) of the patients in groups 1, 2, and 3 were recurrence free, and 90.0%, 87.7%, and 88.2% (log-rank test, p=0.593) of the patients, respe...Continue Reading

References

Apr 20, 2001·Journal of the National Cancer Institute·J L AuInternational Mitomycin C Consortium

Citations

Nov 30, 2010·World Journal of Urology·Alon Z WeizerJeffrey S Montgomery
Oct 17, 2014·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Teng LiMin Chen
Nov 30, 2010·Expert Review of Anticancer Therapy·Rianne J M Lammers, J Alfred Witjes
Oct 4, 2012·Expert Review of Anticancer Therapy·Willem Oosterlinck, Karel Decaestecker
Jun 14, 2008·Expert Opinion on Investigational Drugs·J Alfred Witjes, Prasad S Kolli
Mar 6, 2012·Actas urologicas españolas·Marko BabjukAsociación Europea de Urología
Nov 8, 2011·Urologic Oncology·Yair LotanBladder Cancer Advocacy Network
Apr 5, 2011·European Urology·Marko BabjukEuropean Association of Urology (EAU)
Nov 17, 2009·The Journal of Urology·Ashish M Kamat, Yair Lotan
Sep 25, 2009·European Urology·Giacomo NovaraWalter Artibani
Mar 30, 2010·BJU International·Paolo PuppoAURO.it guideline committee
Feb 3, 2010·BJU International·Benjamin E AyresAction for Bladder Cancer
Dec 21, 2010·European Urology·Willem OosterlinckEuropean Association of Urology Guidelines Committee on Non-Muscle-Invasive Bladder Tumors
Apr 1, 2014·The Journal of Urology·Ashish M KamatJoan Palou
Mar 13, 2018·Expert Review of Anticancer Therapy·Willem Oosterlinck, Karel Decaestecker
Sep 12, 2012·Urologia Internationalis·Laura S MertensSimon Horenblas
Jul 2, 2014·Nature Reviews. Urology·Laura S MertensBas W G van Rhijn
Jan 14, 2011·Nature Reviews. Urology·Johannes Falke, J Alfred Witjes
Jun 26, 2009·Current Opinion in Urology·Roel Peter Engel, J Alfred Witjes
Aug 2, 2008·Current Opinion in Urology·Joerg Schmidbauer, Gabriele Lindenau

Related Concepts

Intravesical Injection
Antibiotics, Cytotoxic
Malignant Neoplasm of Urinary Bladder
Carcinoma, Transitional Cell
Cystoscopic Surgical Procedures
Drug Administration Schedule
Neoplasm Invasiveness
TNM Staging System
Farmorubicina

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.